Objective: The aim: Multiple sclerosis (MS) is a disease of the central nervous system (CNS) characterized by inflammation and demyelination, which leads to chronic progressive disability. Fingolimod is the first registered oral disease-modifying drug (DMD) approved for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS). Fingolimod statistically significantly reduced the number of relapses, clinical and radiological disease activity and disability progression. However, fingolimod can be associated with an increased risk of cancer. This study is aimed to underline how important is regular specialist follow-up during fingolimod therapy.
Patients and methods: Materials and methods: The literature review was conducted using the key words: "fingolimod", "multiple sclerosis", "fingolimod and cancer", "relapsing-remitting multiple sclerosis", "fingolimod adverse effects", "basal cell carcinoma fingolimod", "squamous cell carcinoma fingolimod". The study is based on the case report of a 67-year-old male patient with metachronous skin cancer treated with fingolimod. The drug had an influence on the inhibition of clinical and radiological activity of the disease. Despite the control of the underlying disease, skin cancers occurred during treatment. Basal cell carcinoma and squamous cell carcinoma were diagnosed at an early stage when complete resection was possible and negative (R0) margin resection was achieved.
Conclusion: Conclusions: Dermatological examination should be performed at the beginning and during treatment with fingolimod. Patients need to be informed about the risk of malignancy. Patient education are crucial during treatment, which allows achieving a good therapeutic effect, thus minimizing the risk of malignancy and enabling its early detection and cure.
Keywords: basal cell carcinoma; fingolimod; metachronous skin cancer; multiple sclerosis; relapsing- remitting multiple sclerosis; squamous cell carcinoma.